Definium Therapeutics, Inc. (DFTX) Key Metrics
DFTX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.31B
- Enterprise value
- $4.01B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 5.5 10-yr median 2.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.19
DFTX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsDFTX valuation Price multiples at each fiscal year-end price.
DFTX returns How much profit the business earns on the capital it uses.
DFTX per-share figures Results divided by the shares outstanding at year-end.
DFTX financial health Debt, liquidity and how easily interest is covered.
DFTX valuation history
DFTX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
DFTX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
DFTX price vs earnings per share
DFTX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.20B | — | $143.3M | $67.9M | $566.7M | — | — | — | — | — |
| Enterprise value | $825.1M | — | $57.7M | −$74.2M | $433.2M | — | — | — | — | — |
| Price / book | 3.6 | — | 1.8 | 0.4 | 3.7 | — | — | — | — | — |
| Earnings yield | −15.4% | — | −66.8% | −83.7% | −16.4% | — | — | — | — | — |
| Free cash flow yield | −11.0% | — | −44.9% | −73.9% | −8.1% | — | — | — | — | — |
| Share price at fiscal year-end | $13.39 | $6.96 | $3.66 | $2.20 | $20.70 | $45.75 | $0.84 | $0.66 | $4.46 | $8.23 |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Earnings per share | −$2.06 | — | −$2.44 | −$1.84 | −$3.40 | — | — | — | — | — |
| Operating cash flow per share | −$1.47 | — | −$1.64 | −$1.62 | −$1.67 | — | — | — | — | — |
| Free cash flow per share | −$1.47 | — | −$1.64 | −$1.62 | −$1.67 | — | — | — | — | — |
| Cash per share | $4.61 | — | $2.55 | $4.61 | $4.88 | — | — | — | — | — |
| Book value per share | $3.72 | — | $2.00 | $4.89 | $5.54 | — | — | — | — | — |
| Tangible book value per share | $3.50 | — | $1.47 | $4.13 | $4.56 | — | — | — | — | — |
| Capex per share | $0.00 | — | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Debt per share | $0.45 | — | $0.36 | $0.00 | — | — | — | — | — | — |
| Shares outstanding | 89.3M | — | 39.2M | 30.9M | 27.4M | — | — | — | — | — |
| Change in shares outstanding | — | — | +26.9% | +12.7% | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −64.1% | −68.0% | −83.6% | −37.5% | −81.8% | −86.8% | −35.6% | −23.0% | −60.2% | −87.4% |
| Return on invested capital (ROIC) | — | — | — | −388.6% | — | — | −12.1% | −24.1% | −86.0% | — |
| Return on assets (ROA) | −49.5% | −50.9% | −65.0% | −34.0% | −75.8% | −80.8% | −34.5% | −22.7% | −58.0% | −72.8% |
| Return on tangible assets | −43.7% | −38.5% | −92.0% | −38.8% | −67.8% | −41.8% | −38.0% | −24.3% | −30.5% | −88.7% |
| Financial health | ||||||||||
| Total debt | $40.6M | $21.9M | $14.1M | $72,000 | — | — | — | — | $15,743 | — |
| Cash & short-term investments | $411.6M | $273.7M | $99.7M | $142.1M | $133.5M | $80.1M | $17,931 | $154,791 | $1.7M | $129,331 |
| Net debt | −$371.0M | −$251.9M | −$85.6M | −$142.1M | −$133.5M | −$80.1M | −$17,931 | −$154,791 | −$1.7M | −$129,331 |
| Debt / equity | 0.12 | 0.09 | 0.18 | 0.00 | — | — | — | — | 0.00 | — |
| Debt / assets | 0.09 | 0.07 | 0.11 | 0.00 | — | — | — | — | 0.00 | — |
| Current ratio | 6.29 | 7.25 | 3.22 | 8.16 | 13.18 | 27.10 | 14.76 | 24.14 | 22.03 | 1.80 |
| Quick ratio | 6.29 | 7.25 | 3.22 | 8.16 | 13.18 | 27.10 | 14.76 | 24.14 | 22.03 | 1.80 |
| Interest coverage | -30.3 | -45.5 | -102.0 | -44.4 | -261.4 | -201.4 | — | — | — | — |
| Working capital | $352.6M | $242.8M | $71.6M | $128.2M | $126.8M | $78.5M | $2.7M | $190,400 | $1.7M | $60,719 |
| Invested capital | −$38.7M | −$10.4M | −$7.4M | $8.8M | $18.1M | −$4.2M | $2.7M | $3.4M | $2.3M | −$2,052 |
| Tangible asset value | $312.4M | $221.5M | $57.7M | $127.3M | $124.9M | $75.9M | $2.7M | $3.5M | $3.9M | $127,279 |
| Net current asset value | $311.5M | $220.9M | $57.5M | $127.0M | $124.9M | $75.9M | $2.7M | $190,400 | $1.7M | $60,719 |
| Graham net-net per share | $3.40 | — | $1.36 | $3.99 | $4.43 | — | — | — | — | — |
| Capital allocation | ||||||||||
| Capex / depreciation | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.90 | 156.23 | 390.77 | — |
| Efficiency | ||||||||||
| Days of inventory on hand | — | — | — | — | — | — | 0.0 | 0.0 | — | — |
| Days payables outstanding | — | 2,128.4 | 360.6 | — | — | — | — | — | — | — |
| Receivables turnover | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | — | 0.17 | 1.01 | — | — | — | — | — | — | — |
| Inventory turnover | — | — | — | — | — | — | — | 7,507.37 | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | — | — | — | $6,659 | $9,260 | $7,578 | $2,618 |
| Average payables | $3.7M | $3.1M | $3.1M | $3.1M | $3.1M | $2.0M | — | — | — | — |
| Average inventory | — | — | — | — | — | — | $0 | $1 | — | −$0 |
| Intangibles / total assets | 4.5% | 6.6% | 16.4% | 13.9% | 16.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from DFTX's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
DFTX valuation and financial ratios
Definium Therapeutics earned a return on equity of −64.1% in fiscal 2025. It ended the year with $40.6 million of debt and $411.6 million in cash and short-term investments, a net cash position of $371.0 million.
See the DFTX income statement, the DFTX chart for price history, or the DFTX stock overview for the latest quote and news.
DFTX key metrics FAQ
What is Definium Therapeutics's return on equity?
Definium Therapeutics's return on equity (ROE) was −64.1% in fiscal 2025: net income of -$183.8 million on average shareholders' equity of $286.9 million.
How much debt does Definium Therapeutics have?
Definium Therapeutics had total debt of $40.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.12 and more cash than debt.
What is Definium Therapeutics's free cash flow yield?
Definium Therapeutics generated -$131.6 million of free cash flow in fiscal 2025, a free cash flow yield of −11.0% on its market value at year-end ($1.2 billion).
What is Definium Therapeutics's current ratio?
Definium Therapeutics's current ratio was 6.29 at the end of fiscal 2025: current assets were 6.29 times current liabilities.